Anonymous ID: 33884e March 21, 2021, 8:38 a.m. No.13268496   🗄️.is 🔗kun   >>8606 >>8680 >>8683 >>8722 >>8859 >>9132

>>13267347 pb

 

Reading the transcript to see Pfizer talk about jacking vaccine price. One page in and they can't help brag about bringing in $15B in COVID revenue.

 

>https://dryburgh.com/wp-content/uploads/2021/03/pfizer-usq_transcript_2021-03-11.pdf

 

>BigPharma guilty of crimes against humanity

Anonymous ID: 33884e March 21, 2021, 9:11 a.m. No.13268680   🗄️.is 🔗kun   >>8683 >>8685 >>8690 >>8777 >>8859 >>9132

>>13268496

Anon notes from Pfizer answering Barclays Bank analyst questions:

 

Pic 1 P is seeding the idea of a third dose for "emerging variants".Pic 2 P seeds the idea of annual COVID vaccine "for the foreseeable future". This is all known to anons.

Look at Pic 3. This is down right evil talking about the drug VYNDAQEL. This drug is used to treat cardiomyopathy, which can be caused by the Wuhan virus.

https://www.drugs.com/pro/vyndaqel.html

https://www.mayoclinic.org/diseases-conditions/cardiomyopathy/symptoms-causes/syc-20370709

 

To summarize they are trying to actively infect as many as possible with COVID via world wide vaccination, increase cost/vaccine, and then profit on the backend when a percentage of pop inevitably have major complications requiring MORE DRUGS.

Wow nice business model fuckers. I'll stick with good diet, exercise, and sunlight thank you very much.

Anonymous ID: 33884e March 21, 2021, 9:29 a.m. No.13268736   🗄️.is 🔗kun   >>8748

>>13268722

It is disgusting.

Page 5 mRNA is the future of slave control:

Charles E. Triano - Pfizer Inc. - SVP of IR

And Frank, I would just add, probably similar to the COVID vaccine where we had several different variants of the vaccine when we went into the

COVID studies, we'd probably take the same approach with an influenza vaccine, take a few different modifications of the vaccine and look at it

that way.

We also have said, without being specific, but we have said that the platform mRNA itself, we expect, will provide another leg of the stool, so to

speak, of our vaccines research platform. In terms of other applications, beyond flu and beyond COVID, we haven't been specific at this point, but

given how much we've learned through this process, we do see that there are potential even additional opportunities for this platform.